Abstract: The present disclosure relates generally to systems and processes for assessing and differentiating asthma and chronic obstructive pulmonary disease (COPD) in a patient, and more specifically to computer-based systems and processes for providing a predicted diagnosis of asthma and/or COPD. In accordance with one or more examples, a computing system receives a set of patient data corresponding to a first patient and determines whether the set of patient data satisfies a set of one or more data-correlation criteria. If the set of one or more data-correlation criteria are satisfied, the computing system applies a first diagnostic model to the set of patient data and determines a first predicted diagnosis of asthma and/or COPD. If the set of one or more data-correlation criteria are not satisfied, the computing system applies a second diagnostic model to the set of patient data and determines a second predicted diagnosis of asthma and/or COPD.

Abstract: The present disclosure relates generally to systems and processes for assessing and differentiating asthma and chronic obstructive pulmonary disease (COPD) in a patient, and more specifically to computer-based systems and processes for providing a predicted diagnosis of asthma and/or COPD. In accordance with one or more examples, a computing system receives a set of patient data corresponding to a first patient and determines whether the set of patient data satisfies a set of one or more data-correlation criteria. If the set of one or more data-correlation criteria are satisfied, the computing system applies a first diagnostic model to the set of patient data and determines a first predicted diagnosis of asthma and/or COPD. If the set of one or more data-correlation criteria are not satisfied, the computing system applies a second diagnostic model to the set of patient data and determines a second predicted diagnosis of asthma and/or COPD.

Abstract: The invention provides a method of treating chronic rhinosinusitis such as allergic fungal sinusitis comprising daily oral administration of a composition from more than 500 mg to about 800 mg, preferably about 625 mg or 725 mg terbinafine base equivalent as hydrochloride, or a molar equivalent in other acid addition salt or free base form, for a duration effective to reduce the symptoms of, or eliminate chronic rhinosinusitis; it further concerns the use of terbinafine in the manufacture of a corresponding medicament, and packs containing a plurality of corresponding compositions and medicaments.